Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403).
about
Gefitinib in the treatment of nonsmall cell lung cancer with activating epidermal growth factor receptor mutationPulmonary Toxicities of Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis of Randomized Controlled TrialsMolecular pathology of lung cancer: key to personalized medicine.Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer.Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC)International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinomaTAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer CellsIncreased survival with the combination of stereotactic radiosurgery and gefitinib for non-small cell lung cancer brain metastasis patients: a nationwide study in Taiwan.Therapeutic value of quinazoline-based compounds in prostate cancer.Important factors for achieving survival of five years or more in non-small cell lung cancer patients with distant metastasis.Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC).Management of patients with advanced non-small cell lung cancer: role of gefitinibScreening for EGFR and KRAS mutations in endobronchial ultrasound derived transbronchial needle aspirates in non-small cell lung cancer using COLD-PCR.Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations.Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLCDifferent efficacy of EGFR tyrosine kinase inhibitors and prognosis in patients with subtypes of EGFR-mutated advanced non-small cell lung cancer: a meta-analysisTargeting mTOR to overcome epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer cellsEpidermal growth factor receptor in relation to tumor development: EGFR-targeted anticancer therapy.Gefitinib in non small cell lung cancerThe emerging role of epidermal growth factor receptor (EGFR) inhibitors in first-line treatment for patients with advanced non-small cell lung cancer positive for EGFR mutationsGenotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalitiesFuzheng Kang'ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trialPretreatment levels of the serum biomarkers CEA, CYFRA 21-1, SCC and the soluble EGFR and its ligands EGF, TGF-alpha, HB-EGF in the prediction of outcome in erlotinib treated non-small-cell lung cancer patientsPart 4: pharmacogenetic variability in anticancer pharmacodynamic drug effects.Targeted therapies for non-small cell lung cancer: an evolving landscape.EGFR protein expression in non-small cell lung cancer predicts response to an EGFR tyrosine kinase inhibitor--a novel antibody for immunohistochemistry or AQUA technology.Biomarkers that currently affect clinical practice: EGFR, ALK, MET, KRASEpidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapyAn Analysis of EGFR Mutations among 1506 Cases of Non-Small Cell Lung Cancer Patients in Guangxi, China.Personalized targeted therapy for lung cancerEfficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in targeted therapy of lung squamous cell carcinoma patients with EGFR mutation: a pooled analysis.Review of the treatment of non-small cell lung cancer with gefitinib.Skin rash by gefitinib is a sign of favorable outcomes for patients of advanced lung adenocarcinoma in Japanese patientsEGFR-targeted therapy for non-small cell lung cancer: focus on EGFR oncogenic mutation.Scientific challenges and implementation barriers to translation of pharmacogenomics in clinical practice.Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer.Disruptions in Liver Function among Cancer Patients and Patients Treated with Tyrosine Kinase Inhibiting Drugs: Comparisons of Two Population-Based DatabasesThe Role of Gefitinib in Patients with Non-small-cell Lung Cancer in India.Molecularly targeted approaches herald a new era of non-small-cell lung cancer treatment.
P2860
Q26739096-85C45334-6FA3-4A19-9981-6F07E3CDC796Q26768125-147BF687-D90A-4BA8-BC71-3D72504135F5Q27691299-2B33270D-DEC2-4CE0-BF3C-BDEB76745281Q27852235-A2EFF644-1806-4634-9164-215B6FFA6E6FQ28284519-CF3AD332-0EFC-44A0-9B10-A9C7F1C76EE5Q28303718-2D85C307-3FE5-49D1-B613-F2565E3C66BBQ28548485-B35EF0E7-FD46-42D0-98E9-D77EBA85BBBBQ30279226-EA70C5C0-F892-4E9E-AA38-A5548EC01441Q33746225-10768803-6ACE-4450-8620-2342D7A8271CQ33778280-42E02F29-6297-4147-96F9-9E3E85F4FAF9Q33892582-0BD2D035-515A-4B7F-AE96-E2757D14D515Q33892597-9098DE15-26E3-4A92-9166-C8BD554C98B8Q34032012-404DB874-9B87-436D-A05B-B8584C1BDF44Q34158952-E144FDAF-FC97-40F8-8474-31D6A802FF73Q34307548-EF7D2053-5745-4D66-9216-D7440642C439Q34311186-9949870D-4165-4978-98FF-7A96C0CBF8CFQ34333839-F579B50A-CA85-474D-9941-4222ADE45793Q34852951-EEAC0551-C039-4269-81EF-D1573138C60EQ35013457-6CF17EF5-ED34-4184-A7D8-923FE106CA96Q35031807-FF31CC8C-A064-45D9-8DEE-893F7CE49689Q35076292-78AB77C1-99EF-489A-80AB-C1373CC0FDEBQ35146927-0AEFB767-45EC-4E28-9E73-81A7117E1954Q35404376-053C9317-9D60-47BC-A14A-A69CC6FEC6E8Q35478632-6B90ADB5-494F-41B1-9C31-93E7B3AFB9AAQ35584647-CB1284A7-7C9E-4761-9BB0-2460553A31ABQ35628597-669DC2C7-D030-4C5C-9619-687902C06709Q35699888-DED52866-CBE0-4F50-A59A-E0881F133DE2Q36040606-AEB9D404-D140-4EE4-9DB3-90C3906539FFQ36071392-39DF81ED-5BCF-413E-91D5-DBC49F2C61CEQ36228469-0AD053E0-7E8F-45D2-A39A-2A1B33933125Q36321826-731E0140-7950-4653-856A-B78C22B2EBE7Q36352476-6B87D5A0-F6CD-4B05-AA8F-8172796BE922Q36461805-361600D2-96AB-4D2C-8B97-D282CEB9FF51Q36601975-227BA98D-7A70-4746-AD45-5D3CD1E13F6EQ36619212-0E1A7503-C276-4FAA-9402-89FC2B083D31Q36702588-DA283D19-4674-43ED-950D-588F7044EF3CQ36817080-C9758985-E6DC-49C2-A067-B4F457EC8F15Q36845060-E0D2329A-A200-43BF-B555-E7F4A266203BQ36924217-3DA71342-2D5C-4BC5-838E-C987380AFD60Q36929734-4E5DFB83-E06A-4734-9226-46D691B3ECC0
P2860
Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403).
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Multicentre prospective phase ...... ology Group trial (WJTOG0403).
@ast
Multicentre prospective phase ...... ology Group trial (WJTOG0403).
@en
type
label
Multicentre prospective phase ...... ology Group trial (WJTOG0403).
@ast
Multicentre prospective phase ...... ology Group trial (WJTOG0403).
@en
prefLabel
Multicentre prospective phase ...... ology Group trial (WJTOG0403).
@ast
Multicentre prospective phase ...... ology Group trial (WJTOG0403).
@en
P2093
P2860
P356
P1476
Multicentre prospective phase ...... ology Group trial (WJTOG0403).
@en
P2093
N Katakami
P2860
P2888
P304
P356
10.1038/SJ.BJC.6604249
P407
P577
2008-02-19T00:00:00Z
P5875
P6179
1018815805